FOR IMMEDIATE RELEASE

Contact: Andrew Krouse
(434) 974-6969
krouse@tautherapeutics.com
www.tautherapeutics.com

Tau Therapeutics LLC to Present Poster on Mibefradil as a Radiation Therapy Enhancer
Mibefradil Enhances the Effect of Radiation Therapy in an Intracranial Glioma Model

(Charlottesville, VA – November 13, 2012) Tau Therapeutics LLC announced today that academic collaborator, University of Virginia Professor Jason Sheehan, MD, PhD and colleagues, will present a poster at the Society of Neuro-Oncology's 17th annual meeting in Washington, DC, November 15 – 18, 2012. The poster entitled, "Mibefradil Enhances the Tumoricidal Effect of Radiation Therapy in an Intracranial Glioma Model" will highlight Tau's product candidate mibefradil in the company's Interlaced Therapy™ approach as a radiation therapy enhancer for the treatment of brain cancer. Tau's proprietary Interlaced Therapy™ is the sequential administration of a T-type calcium channel inhibitor prior to the administration of conventional radiation or chemotherapy.

"Dr. Sheehan's results have exciting implications for radiation therapy across many tumor types," said Dr. Lloyd Gray, Chief Scientific Officer of Tau Therapeutics LLC. "We are encouraged to see that mibefradil is capable of enhancing both radiation and chemotherapy in pre-clinical models."

Interlaced Therapy™ is the sequential administration of a T-type calcium channel blocker to control and synchronize dividing cancer cells followed by the administration of a standard chemotherapy to more efficiently and effectively kill the cancer cells. In pre-clinical models, T-type calcium channel blockade with Tau's drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.

Tau is currently conducting a Phase Ib clinical trial studying mibefradil as a potential chemotherapy enhancer in brain cancer in conjunction with the NCI's Adult Brain Tumor Consortium.

About Tau Therapeutics

Tau Therapeutics, a privately held oncology company based in Charlottesville, VA, is at the forefront of cancer research focusing on controlling the proliferation pathway rather than a specific protein or growth factor. Tau's Interlaced Therapy™ is built on the rationale that using a T-type calcium channel inhibitor to increase the proportion of cancer cells and cancer stem cells at the point of maximum metabolic vulnerability in S phase will increase cell death caused by cytotoxic chemotherapies. By more effectively reducing tumor burden and killing the cells that cause recurrence, Tau believes it will offer a significant advancement in the treatment of cancer.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics, LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.